# EDGAR Filing Document

**Accession Number:** 0001833141
**File Stem:** 0001833141-26-000041
**Filing Date:** 2026-6
**Character Count:** 11302
**Document Hash:** c0c4c093343e7833a6ca918559992e72
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001833141-26-000041.hdr.sgml**: 20260625

**ACCESSION NUMBER**: 0001833141-26-000041

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260625

**FILED AS OF DATE**: 20260625

**DATE AS OF CHANGE**: 20260625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYBIN INC.
- **CENTRAL INDEX KEY:** 0001833141
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40673
- **FILM NUMBER:** 261118735

**BUSINESS ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9
- **BUSINESS PHONE:** (908) 764-8385

**MAIL ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

For the month of June, 2026.

Commission File Number: **001-40673**

****<br>**<u>Cybin Inc.</u>**<br>(Exact Name of Registrant as Specified in Charter)<br>**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>

---

| | | | |
|:---|:---|:---|:---|
| | | **CYBIN INC.** | **CYBIN INC.** |
| | | (Registrant) | (Registrant) |
| Date: | June 25, 2026 | By: | */s/ Greg Cavers&nbsp;&nbsp;&nbsp;&nbsp;*  |
|  |  | Name: | Greg Cavers |
|  |  | Title: | Chief Financial Officer |

---

------

**<u>EXHIBIT INDEX</u>**

99.1 <u>[News Release dated June 25, 2026](finalpressrelease-closingo.htm)</u>

## Exhibit 99.1

![image_0a.jpg](image_0a.jpg)

**HELUS PHARMA**<sup>TM</sup> **ANNOUNCES CLOSING OF US$50 MILLION UNDERWRITTEN OFFERING** 

NEW YORK & TORONTO – June 25, 2026 – Helus Pharma<sup>TM</sup> (Nasdaq: HELP) (Cboe CA: HELP) (the "**Company**" or "**Helus Pharma**"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("**NSAs**"), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the "**Common Shares**") at an offering price of US$4.85 per Common Share for aggregate gross proceeds of US$50 million (the "**Offering**").

Cantor and Barclays acted as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets acted as lead managers for the Offering.

The Company intends to use the net proceeds from the Offering to progress the Company's HLP003 for major depressive disorder with Phase 3 APPROACH data expected in the fourth quarter of 2026, HLP004 for generalized anxiety disorder, and HLP005 programs, and for working capital and general corporate purposes.

The Company offered the Common Shares only in the United States and in certain other jurisdictions outside of Canada, pursuant to a prospectus supplement (the "**Prospectus Supplement**") to the Company's short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025 (the "**Base Shelf Prospectus**"). The Prospectus Supplement was filed with the securities commissions in all of the provinces and territories of Canada and with the United States Securities and Exchange Commission (the "**SEC**"), as part of a registration statement on Form F-10 (File No. 333-292294) which was filed with the SEC, under the United States Securities Act of 1933, as amended, on December 19, 2025, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. The Base Shelf Prospectus, the Prospectus Supplement and the documents incorporated by reference therein, including any marketing materials, are available on the Company's SEDAR+ profile at <u>www.sedarplus.ca</u> and the Company's EDGAR profile at <u>www.sec.gov/edgar</u>. An electronic or paper copy of the Base Shelf Prospectus and the Prospectus Supplement may be obtained, without charge, by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at (888) 603-5847, or via e-mail at Barclaysprospectus@broadridge.com.

In consideration for their services, the Company paid to the underwriters a cash commission of US$3 million.

&nbsp;&nbsp;&nbsp;&nbsp;

------

*This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.*

**About Helus Pharma**

Helus Pharma<sup>TM</sup>, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has a portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. Helus Pharma<sup>TM</sup> is a trademark of Helus Pharma Corp.

**Cautionary Notes and Forward-Looking Statements**

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's intended use of proceeds, and the Company's ability to address the need for treatment options for people who suffer from depression, anxiety and other mental health conditions.

&nbsp;&nbsp;&nbsp;&nbsp;

------

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at <u>www.sedarplus.ca</u> and the Company's EDGAR profile at <u>www.sec.gov/edgar</u>. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004, and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

*Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.*

&nbsp;&nbsp;&nbsp;&nbsp;

------

**Investor Contact:**<br>Matthew Beck<br>astr partners<br>Managing Partner<br>(917) 415-1750<br>matthew.beck@astrpartners.com

George Tziras

Chief Business Officer

Helus Pharma

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

**Media Contact:**<br>Johnny Tokarczyk<br>RXMD<br>Public Relations Director<br>jtokarczyk@rxmedyn.com<br>(914) 772-7562

&nbsp;&nbsp;&nbsp;&nbsp;